Bayer Schering acquires Japanese Alzheimer's imaging agents
This article was originally published in Scrip
Bayer Schering Pharmahas licensed from the University of Nagasaki in Japan a series of molecules for use in the positron emission tomography imaging and diagnosis of Alzheimer's disease. The fluorine-18-labelled tracers bind to amyloid beta protein, the accumulation of which has been linked to the development of the disorder. At present, a diagnosis can only be confirmed through autopsy; the molecular imaging agents may enable much earlier detection and treatment, said the company, which holds exclusive global development and marketing rights.